The RSI Oscillator for BNTC moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 21 of the 23 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 61 cases where BNTC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for BNTC just turned positive on October 20, 2026. Looking at past instances where BNTC's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Following a +1.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTC advanced for three days, in 226 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNTC as a result. In 91 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The 50-day moving average for BNTC moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for BNTC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. BNTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.829) is normal, around the industry mean (3.051). P/E Ratio (-9.469) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. BNTC's P/S Ratio (2500.000) is slightly higher than the industry average of (439.647).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The RSI Oscillator for IKT moved into overbought territory on November 03, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for IKT just turned positive on October 29, 2026. Looking at past instances where IKT's MACD turned positive, the stock continued to rise in 43 of 48 cases over the following month. The odds of a continued upward trend are 90%.
Following a +6.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where IKT advanced for three days, in 196 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
IKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for IKT entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.424) is normal, around the industry mean (3.051). P/E Ratio (-3.557) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. IKT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BNTC | IKT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 84 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 77 | 65 | |
P/E GROWTH RATING 1..100 | 16 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 45 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IKT's Valuation (27) in the null industry is somewhat better than the same rating for BNTC (84) in the Biotechnology industry. This means that IKT’s stock grew somewhat faster than BNTC’s over the last 12 months.
IKT's Profit vs Risk Rating (100) in the null industry is in the same range as BNTC (100) in the Biotechnology industry. This means that IKT’s stock grew similarly to BNTC’s over the last 12 months.
BNTC's SMR Rating (97) in the Biotechnology industry is in the same range as IKT (98) in the null industry. This means that BNTC’s stock grew similarly to IKT’s over the last 12 months.
IKT's Price Growth Rating (65) in the null industry is in the same range as BNTC (77) in the Biotechnology industry. This means that IKT’s stock grew similarly to BNTC’s over the last 12 months.
BNTC's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for IKT (98) in the null industry. This means that BNTC’s stock grew significantly faster than IKT’s over the last 12 months.
| BNTC | IKT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 89% | N/A |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 88% |
| Advances ODDS (%) | 7 days ago 83% | 7 days ago 84% |
| Declines ODDS (%) | 2 days ago 89% | 2 days ago 89% |
| BollingerBands ODDS (%) | N/A | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNTC’s FA Score shows that 1 FA rating(s) are green while IKT’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BNTC’s TA Score shows that 4 TA indicator(s) are bullish while IKT’s TA Score has 5 bullish TA indicator(s).
BNTC (@Biotechnology) experienced а -3.23% price change this week, while IKT (@Biotechnology) price change was -5.73% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.31%. For the same industry, the average monthly price growth was -10.93%, and the average quarterly price growth was -16.13%.
BNTC is expected to report earnings on Nov 13, 2026.
IKT is expected to report earnings on Nov 13, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, IKT has been loosely correlated with MLYS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if IKT jumps, then MLYS could also see price increases.
| Ticker / NAME | Correlation To IKT | 1D Price Change % | ||
|---|---|---|---|---|
| IKT | 100% | -3.90% | ||
| MLYS - IKT | 41% Loosely correlated | +2.83% | ||
| EDIT - IKT | 37% Loosely correlated | +1.17% | ||
| BNTC - IKT | 37% Loosely correlated | -1.06% | ||
| VIR - IKT | 37% Loosely correlated | +2.00% | ||
| ENTA - IKT | 36% Loosely correlated | -0.58% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BTGD | 23.15 | 0.30 | +1.33% |
| STKd 100% Bitcoin & 100% Gold ETF (BTGD) | |||
| SDG | 86.90 | 0.27 | +0.31% |
| iShares MSCI Global Sustainable Development Goals ETF (SDG) | |||
| MMU | 9.49 | 0.01 | +0.11% |
| Western Asset Managed Municipals Fund | |||
| ALRG | 30.89 | N/A | N/A |
| Allspring LT Large Core ETF (ALRG) | |||
| HYD | 49.02 | -0.32 | -0.65% |
| VanEck High Yield Muni ETF (HYD) | |||